Thursday, April 25, 2024
4/25/2024
Summary Cryptosporidium remains a significant AIDS-related opportunistic infection among people with late HIV diagnosis or without access to HAART. This parasite infects the gastrointestinal epithelium in humans; infection is also a common cause of diarrhea in young children in developing countries. There is currently no fully effective therapy available for the infection. Cryptosporidium has been referred as a “minimally invasive” mucosal pathogen, and epithelial antimicrobial defense is key to mucosal innate anti-Cryptosporidium immunity. Whereas it is well appreciated that Type II interferon-gamma (IFN-¿) is required for preventing development of intestinal cryptosporidiosis, recent advances have revealed a significant Type I IFN response (e.g., induction of IFN-alpha and IFN-beta) in host epithelium following C. parvum infection. The molecular mechanisms underlying Type I IFN response and its potential role in the pathogenesis of cryptosporidiosis are unclear. Cryptosporidium parvum virus 1 (CSpV1) is a member of the family Partitiviridae, genus Cryspovirus that infects C. parvum and other Cryptosporidium spp. Our recent studies demonstrate that host delivery of CSpV1-RNAs at the host-parasite interface can trigger a Type I IFN response in host cells. C. parvum infection attenuates intestinal epithelial cell response to IFN-¿ stimulation (i.e., infected cells are less susceptible to activation by IFN-¿). Surprisingly, knockout Type I IFN signaling in intestinal epithelial cells or inhibition of CSpV1-RNA delivery can restore cellular response to IFN-¿ stimulation and promotes resistance to C. parvum infection, suggesting a negative impact of Type I IFN signaling on epithelial anti-Cryptosporidium defense. Based on these observations, we hypothesize that cryptosporidial infection triggers Type I IFN response in the intestinal epithelium and attenuates IFN-¿-mediated epithelial antimicrobial defense through delivery of CSpV1- RNAs. We will use in vitro, ex vivo, and in vivo infection models and complementary biochemical, molecular, and morphologic approaches to elucidate the molecular mechanisms by which Cryptosporidium infection triggers Type I IFN gene transcription in the intestinal epithelium (Aim 1), determine how Cryptosporidium infection modulates the JAK/STAT signaling in infected intestinal epithelial cells (Aim 2), and define the impact of Cryptosporidium-induced JAK/STAT signaling dysregulation on epithelial anti-parasite defense (Aim 3). The proposal is conceptually innovative as it tests a novel mechanism for symbiotic CSpV1 in the pathogenesis of cryptosporidiosis and has the potential to inform future development of new therapeutic strategies.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
